A day of stark contrasts in global health: a potentially catastrophic Ebola outbreak in the Democratic Republic of the Congo remains unchecked, while US regulators rejected a Chinese lung cancer drug and approved a new therapy for a kidney disease, and Johnson & Johnson moved to acquire an eye disease biotech.
Ebola outbreak in DR Congo still not under control
The Africa CDC warned that the Ebola outbreak in the Democratic Republic of the Congo is still not under control six months after it was declared, with more than 11,200 cases and 5,500 deaths recorded. The director-general, Jean Kaseya, said it could become the world's worst if not stopped now.
Our story: Africa CDC warns Ebola outbreak in DR Congo not under control six months on
FDA rejects Chinese lung cancer drug ivonescimab
The New York Times and Financial Times reported that the FDA rejected ivonescimab, a lung cancer drug developed in China, dealing a blow to Beijing's biotech sector.
Reported by The New York Times
Reported by Financial Times
Gazyva approved for primary membranous nephropathy
The Financial Times reported that the FDA approved Genentech's Gazyva as the first treatment for primary membranous nephropathy.
Reported by Financial Times
Johnson & Johnson eyes eye disease biotech
Johnson & Johnson is looking to buy a biotech company focused on eye diseases for up to $3.4 billion, according to the Financial Times.
Reported by Financial Times
Checked
10 claims in this story checked against 3 sources: 4 supported.
Show each claim
- SupportedThe Ebola outbreak is not under control.Al Jazeera – Breaking News, World News and Video from Al Jazeera: “Africa’s top public health agency says the Ebola outbreak in the Democratic Republic of the Congo (DRC) is still not under control six months after it was declared.”
- SupportedThe FDA rejected a Chinese lung cancer drug.NYT > U.S. > Politics: “F.D.A. Rejects Closely Watched Lung Cancer Drug From China.”
- Not in the sourcesRegulatory actions and a worsening outbreak dominate health news.Al Jazeera – Breaking News, World News and Video from Al Jazeera: ““Transmission is slowing in several early epicentres, and clinical trials, including the Tumaini trial and new vaccine candidates, are advancing rapidly””
- Partly supportedThe outbreak is potentially catastrophic.Al Jazeera – Breaking News, World News and Video from Al Jazeera: ““If we don’t stop this outbreak now, it would be the worst Ebola outbreak that the world will have,” Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention (Africa CDC), told Reuters news agency on Sunday.”
- Partly supportedThe outbreak remains unchecked six months after it was declared.Al Jazeera – Breaking News, World News and Video from Al Jazeera: “Africa’s top public health agency says the Ebola outbreak in the Democratic Republic of the Congo (DRC) is still not under control six months after it was declared.”
- SupportedThe outbreak has recorded more than 11,200 cases and 5,500 deaths.Al Jazeera – Breaking News, World News and Video from Al Jazeera: “Since the outbreak was announced on May 15, more than 11,200 cases and 5,500 deaths have been recorded, according to government data.”
- Partly supportedThe FDA rejected ivonescimab.NYT > U.S. > Politics: “F.D.A. Rejects Closely Watched Lung Cancer Drug From China.”
- SupportedThe New York Times and Financial Times reported the FDA rejection, and the decision dealt a blow to Beijing’s biotech sector."site:ft.com when:1d" - Google News: “FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector - Financial Times.”
- Partly supportedThe FDA approved Genentech’s Gazyva as the first treatment for primary membranous nephropathy."site:ft.com when:1d" - Google News: “Genentech's Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy - Financial Times.”
- Partly supportedJohnson & Johnson moved to acquire an eye-disease biotech for up to $3.4 billion."site:ft.com when:1d" - Google News: “Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn - Financial Times.”